RT info:eu-repo/semantics/article
T1 Comparative evaluation of dynamic risk stratification according to ATA 2015 and ATA 2025 in low-risk differentiated thyroid cancer without radioiodine ablation
A1 Fernández Velasco, Pablo
A1 Peciña Melgosa, Paula
A1 Torres Torres, Beatriz
A1 Torres Morientes, Luis Miguel
A1 Fernández Rodríguez, Ana
A1 Alonso Mesonero, Marta
A1 Uribe Viloria, Marta de
A1 Álvarez Quiñones, María
A1 Santos Pérez, Jaime
A1 Luis Ramón, Daniel de
A1 Díaz Soto, Gonzalo
K1 Endocrinología
K1 Oncología
K1 Patología
K1 Carcinoma diferenciado de tiroides
K1 Estratificación dinámica del riesgo
K1 Directrices de la ATA
K1 Tiroglobulina
K1 Anticuerpos antitiroglobulina
K1 Cáncer de tiroides de bajo riesgo
K1 3205.02 Endocrinología
K1 3207.13 Oncología
AB Purpuse.To compare dynamic risk stratification (DRS) according to the 2015 American Thyroid Association-Momesso et al. 2016 extension (ATA2015-M) and the 2025 ATA update in low-risk differentiated thyroid cancer (DTC) managed without radioactive iodine (I-131), and to explore the role of an intermediate thyroglobulin (Tg) cutoff of 1 ng/mL.Methods.We conducted a retrospective analysis of a prospectively collected cohort of 74 low-risk DTC patients treated with total thyroidectomy (n = 55) or hemithyroidectomy (n = 19) between 2020 and 2024. Clinical, histopathological, and biochemical data were collected. DRS was assessed at the first follow-up visit (6 months after surgery) and at the last visit (median follow-up 27 months [IQR 16–41]) using ATA2015-M and ATA2025 criteria. An exploratory analysis applying a Tg cutoff of 1 ng/mL was performed.Results.According to ATA2015-M, excellent response (ER) rates in total thyroidectomy patients increased from 49.2% at baseline to 52.8% at final follow-up. In contrast, ATA2025 classified 89.1% as ER at baseline and 98.2% at final follow-up (p < 0.001). Using the intermediate cutoff of 1 ng/mL, ER rates were 80.0% and 89.1%, respectively. Reclassification to ER under ATA2025 was primarily driven by anti-thyroglobulin antibody (TgAb) negativization, as Tg values remained stable and below the new 2.5 ng/mL threshold. No structural incomplete responses were observed.Conclusion.ATA2025 criteria substantially increase ER classification in low-risk DTC patients managed without I-131 compared with ATA2015-M. A 1 ng/mL Tg cutoff may provide a more realistic representation of clinical practice. The dynamic trend of TgAb, rather than their presence alone, is a key determinant for reclassification during follow-up.
PB Springer Nature
SN 1559-0100
YR 2026
FD 2026
LK https://uvadoc.uva.es/handle/10324/82986
UL https://uvadoc.uva.es/handle/10324/82986
LA eng
NO Endocrine, 2026, vol. 91 (Version of record)
NO Producción Científica
DS UVaDOC
RD 23-feb-2026